KEAP1 and breast carcinoma: The results of our experiments showed that ML385 did not affect the expressions of Keap1 and total Nrf2 (T-Nrf2) in breast cancer cells, but significantly reduced the expression of Nrf2 in the nucleus (N-Nrf2) (Figure 5A-B).